U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a ...

The agency identified six cases in Sanofi’s phase 3 program that met Hy’s Law—a rule of thumb for assessing the risk of ...

A phase 3 study of Zenas BioPharma's autoimmune disease candidate has hit its primary endpoint. But, with the result falling ...

Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...

MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...

Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...

Biobeat Technologies has raised $50 million in a series B round to help boost the commercialization of its blood pressure ...

Sanofi has returned to U.S. artificial intelligence research biotech Earendil Labs for another significant autoimmune and ...

In 2025, biopharma layoffs showed no signs of slowing, instead rising 16% year over year. | In 2025, biopharma layoffs showed ...

The June agreement established a fixed revenue-sharing model, with TME Pharma receiving a “larger share of future licensing ...

Right on the heels of its IPO, Insilico Medicine is starting the year with an oncology discovery and development pact with French pharma Servier.  | Right on the heels of its IPO, Insilico Medicine is ...

AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug. | ...